Anavex Life Sciences Corp. (AVXL)
1.19
-0.11
(-8.46%)
USD |
NASDAQ |
Oct 30, 16:00
1.19
0.00 (0.00%)
Pre-Market: 20:00
Anavex Life Sciences Enterprise Value : -8.017M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | -8.017M |
| October 29, 2026 | 2.180M |
| October 28, 2026 | 2.180M |
| October 27, 2026 | 3.107M |
| October 26, 2026 | 0.3259M |
| October 23, 2026 | 4.961M |
| October 22, 2026 | 7.742M |
| October 21, 2026 | 7.742M |
| October 20, 2026 | 7.742M |
| October 19, 2026 | -2.455M |
| October 16, 2026 | 3.107M |
| October 15, 2026 | 18.87M |
| October 14, 2026 | 19.79M |
| October 13, 2026 | 18.87M |
| October 12, 2026 | 21.65M |
| October 09, 2026 | 19.79M |
| October 08, 2026 | 24.43M |
| October 07, 2026 | 23.50M |
| October 06, 2026 | 29.99M |
| October 05, 2026 | 34.16M |
| October 02, 2026 | 50.38M |
| October 01, 2026 | 56.87M |
| September 30, 2026 | 68.92M |
| September 29, 2026 | 100.44M |
| September 28, 2026 | 99.51M |
| Date | Value |
|---|---|
| September 25, 2026 | 102.29M |
| September 24, 2026 | 98.58M |
| September 23, 2026 | 99.51M |
| September 22, 2026 | 110.64M |
| September 21, 2026 | 104.15M |
| September 18, 2026 | 106.00M |
| September 17, 2026 | 105.07M |
| September 16, 2026 | 100.44M |
| September 15, 2026 | 107.85M |
| September 14, 2026 | 122.69M |
| September 11, 2026 | 124.54M |
| September 10, 2026 | 128.25M |
| September 09, 2026 | 136.59M |
| September 08, 2026 | 145.86M |
| September 04, 2026 | 146.79M |
| September 03, 2026 | 145.86M |
| September 02, 2026 | 149.57M |
| September 01, 2026 | 147.71M |
| August 31, 2026 | 141.22M |
| August 28, 2026 | 158.84M |
| August 27, 2026 | 171.82M |
| August 26, 2026 | 182.01M |
| August 25, 2026 | 211.67M |
| August 24, 2026 | 169.96M |
| August 21, 2026 | 182.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vaxcyte, Inc. | 7.610B |
| Foghorn Therapeutics, Inc. | -2.354M |
| Connect Biopharma Holdings Ltd. | 19.63M |
| Caribou Biosciences, Inc. | -40.80M |
| Arrowhead Pharmaceuticals, Inc. | 8.229B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 7.824M |
| Total Expenses (Quarterly) | -7.824M |
| EPS Diluted (Quarterly) | 0.0842 |
| Earnings Yield | -12.74% |
| Normalized Earnings Yield | -12.74 |